Fifth Third Bancorp Has $2.11 Million Holdings in HealthEquity, Inc. $HQY

Fifth Third Bancorp raised its position in shares of HealthEquity, Inc. (NASDAQ:HQY) by 2,370.6% in the first quarter, HoldingsChannel reports. The fund owned 25,200 shares of the company’s stock after acquiring an additional 24,180 shares during the period. Fifth Third Bancorp’s holdings in HealthEquity were worth $2,106,000 as of its most recent filing with the Securities & Exchange Commission.

Other institutional investors and hedge funds also recently made changes to their positions in the company. Sivia Capital Partners LLC acquired a new stake in HealthEquity during the 2nd quarter worth approximately $306,000. Arrowstreet Capital Limited Partnership acquired a new position in HealthEquity in the 2nd quarter valued at $4,747,000. Marshall Wace LLP bought a new position in HealthEquity during the 2nd quarter worth $5,483,000. Amundi increased its position in HealthEquity by 9.3% during the 2nd quarter. Amundi now owns 30,203 shares of the company’s stock worth $3,059,000 after buying an additional 2,574 shares during the period. Finally, Jump Financial LLC acquired a new stake in shares of HealthEquity during the second quarter worth $449,000. Institutional investors and hedge funds own 99.55% of the company’s stock.

HealthEquity Stock Down 1.1%

Shares of NASDAQ HQY opened at $97.77 on Wednesday. The company has a debt-to-equity ratio of 0.46, a quick ratio of 3.44 and a current ratio of 3.44. HealthEquity, Inc. has a 52 week low of $72.76 and a 52 week high of $105.96. The stock has a market capitalization of $8.17 billion, a P/E ratio of 36.62, a PEG ratio of 1.66 and a beta of 0.21. The stock’s fifty day moving average is $89.45 and its 200 day moving average is $84.82.

HealthEquity (NASDAQ:HQY) last posted its quarterly earnings data on Thursday, May 28th. The company reported $1.24 earnings per share for the quarter, topping the consensus estimate of $1.11 by $0.13. The business had revenue of $354.64 million during the quarter, compared to analysts’ expectations of $352.02 million. HealthEquity had a net margin of 17.25% and a return on equity of 14.75%. The company’s quarterly revenue was up 7.2% compared to the same quarter last year. HealthEquity has set its FY 2027 guidance at 2.880-2.950 EPS. Sell-side analysts forecast that HealthEquity, Inc. will post 3.92 earnings per share for the current fiscal year.

Insider Activity at HealthEquity

In other HealthEquity news, Director Gayle Furgurson Wellborn sold 2,439 shares of HealthEquity stock in a transaction dated Thursday, May 28th. The stock was sold at an average price of $90.00, for a total value of $219,510.00. Following the transaction, the director owned 19,733 shares in the company, valued at $1,775,970. The trade was a 11.00% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available at this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, EVP Delano Ladd sold 7,500 shares of the firm’s stock in a transaction that occurred on Thursday, May 28th. The shares were sold at an average price of $90.00, for a total transaction of $675,000.00. Following the completion of the sale, the executive vice president owned 91,141 shares in the company, valued at approximately $8,202,690. The trade was a 7.60% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold 17,905 shares of company stock valued at $1,651,280 over the last ninety days. 1.60% of the stock is owned by corporate insiders.

Analysts Set New Price Targets

A number of brokerages have recently issued reports on HQY. KeyCorp reissued an “overweight” rating on shares of HealthEquity in a research report on Tuesday, May 26th. Royal Bank Of Canada lifted their price objective on shares of HealthEquity from $100.00 to $108.00 and gave the stock an “outperform” rating in a research note on Wednesday, June 3rd. Weiss Ratings raised shares of HealthEquity from a “hold (c)” rating to a “hold (c+)” rating in a report on Friday, June 5th. Citigroup restated a “market outperform” rating on shares of HealthEquity in a research report on Monday, June 1st. Finally, Barrington Research reaffirmed an “outperform” rating and set a $110.00 target price on shares of HealthEquity in a report on Friday, May 22nd. Eleven research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat.com, the company has an average rating of “Moderate Buy” and an average price target of $110.57.

HealthEquity Company Profile

HealthEquity, Inc (NASDAQ: HQY) is a leading administrator of consumer-directed health accounts and related benefit solutions in the United States. Founded in 2002 and headquartered in Draper, Utah, the company specializes in health savings accounts (HSAs) and offers complementary services such as flexible spending accounts (FSAs), health reimbursement arrangements (HRAs), COBRA administration and commuter benefits. Through its technology-driven platform, HealthEquity enables employers, health plans and individuals to streamline account management, improve cost transparency and encourage more informed healthcare spending.

Serving millions of members across all 50 states, HealthEquity leverages an open-architecture ecosystem that integrates with health plans, payroll providers and financial institutions.